Frontlight ResearchEarly access
Taking peoplePhase 2
Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants with moderate to severe Traumatic Brain Injury (TBI).
Key facts
- Who runs it
- Dompe' Farmaceutici S.p.A.
- Where
- Denmark, Finland, France, Germany, Italy, Poland, Spain, and Sweden26 sites in 8 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 146 people, planned
- Started
- 13 Jul 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional
- Record updated
- 10 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male and female adults 18 to 70 years of age
- TBI resulting in hospital evaluation within the last 2-8 weeks prior to informed consent
- A clinical diagnosis of moderate to severe TBI (defined by Glasgow Coma Scale [GCS] score 3 to 12), considering the highest GCS score assessed within 24 hours following injury
- Confirmed TBI diagnosis by computed tomography (CT) assessed by the investigator
- Anticipated discharge to a rehabilitation setting within a facility or at home
Who cannot take part
- Pre-existing medical conditions which can continue to produce functional disability up to the time of injury
- GOS-E score of 7 (lower good recovery) or 8 (upper good recovery) at time of informed consent
- Penetrating TBI (eg, gunshot, stabs)
- Medically refractory brain edema at time of screening
- Dependence on invasive mechanical ventilation without the ability to sustain spontaneous breathing at time of screening
- Poor survival prognosis (investigator assessment)
This trial has no sites in United States.
It has sites in 8 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and tolerability of intranasal cenegermin in participants with moderate to severe subacute TBI.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
- Record updated
- 10 September 2026